Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses

Ya Fan(First Affiliated Hospital Zhejiang University), Jie Sun(North Sichuan Medical University), Yanting Duan, Jiangqing Chen(First Affiliated Hospital Zhejiang University), Kai Shang(Zhejiang University), Yajie Wang(Wenzhou Medical University), He Huang(Peking University), Jie Jiang(Zhejiang University), Chun Zhou(Guangdong Pharmaceutical University), Lu Su(Zhejiang University), Michel Sadelain(Columbia University Irving Medical Center)
Nature Biomedical Engineering
July 14, 2025
10.1038/s41551-025-01450-4
Cited by 15

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
|Nature|2019|659
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551
Up-Regulation of TWIST in Prostate Cancer and Its Implication as a Therapeutic Target
|Cancer Research|2005|467